Table 2.
The susceptibility results of Abs in vitro
| Total (n = 166) |
Death group (n = 45) |
Survival group (n = 121) |
||||
|---|---|---|---|---|---|---|
| S | I | S | I | S | I | |
| Ampicillin/sulbactam | 3/166 | 8/166 | 1/45 | 0/45 | 2/121 | 8/121 |
| Piperacillin | 0/166 | 0/166 | 0/45 | 0/45 | 0/121 | 0/121 |
| Carbapenems* | 9/166 | 0/166 | 4/45 | 0/45 | 5/121 | 0/121 |
| Piperacillin/Tazobactam | 1/166 | 3/166 | 0/45 | 0/45 | 1/121 | 3/121 |
| Ceftriaxone | 0/166 | 4/166 | 0/45 | 1/45 | 0/121 | 3/121 |
| Cefotaxime | 0/166 | 4/166 | 0/45 | 1/45 | 0/121 | 3/121 |
| Cefepime | 2/166 | 3/166 | 1/45 | 1/45 | 1/121 | 2/121 |
| Cefoxitin | 0/166 | 0/166 | 0/45 | 0/45 | 0/121 | 0/121 |
| Gentamicin | 7/166 | 4/166 | 2/45 | 1/45 | 5/121 | 3/121 |
| Tobramycin | 15/166 | 2/166 | 3/45 | 1/45 | 12/121 | 1/121 |
| Amikacin | 12/166 | 1/166 | 3/45 | 0/45 | 9/121 | 1/121 |
| Ciprofloxacin | 4/166 | 0/166 | 1/45 | 0/45 | 3/121 | 0/121 |
| Levofloxacin | 4/166 | 7/166 | 1/45 | 0/45 | 3/121 | 7/121 |
| Moxifloxacin | 4/166 | 0/166 | 1/45 | 0/45 | 3/121 | 0/121 |
| Tetracycline | 3/166 | 6/166 | 1/45 | 0/45 | 2/121 | 6/121 |
| Tigecycline | 161/166 | 5/166 | 44/45 | 1/45 | 117/121 | 4/121 |
| Trimethoprim/Sulfamethoxazole | 17/166 | 0/166 | 5/45 | 0/45 | 12/121 | 0/121 |
| Cefoperazone/Sulbactam | 3/166 | 7/166 | 1/45 | 2/45 | 2/121 | 5/121 |
| Minocyclline | 25/166 | 13/166 | 4/45 | 2/45 | 21/121 | 11/121 |
| Ampicillin | 1/166 | 0/166 | 0/45 | 0/45 | 1/121 | 0/121 |
| Amoxicillin/Clavulanic | 6/166 | 0/166 | 2/45 | 0/45 | 4/121 | 0/121 |
| Aztreonam | 7/166 | 0/166 | 3/45 | 0/45 | 4/121 | 0/121 |
| Cefotetan | 1/166 | 0/166 | 1/45 | 0/45 | 0/121 | 0/121 |
| Cefazolin | 0/166 | 0/166 | 0/45 | 0/45 | 0/121 | 0/121 |
*Carbapenems including Imipenem/Meropenem/Doripenem